Pregnancy Specific Protease Activation of PAR-1 and TET2 in Preeclampsia-Implications for Therapy
先兆子痫中 PAR-1 和 TET2 的妊娠特异性蛋白酶激活——对治疗的影响
基本信息
- 批准号:9306404
- 负责人:
- 金额:$ 32.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:Binding SitesBlood CirculationBlood VesselsCell LineCell NucleusClinicalDNA MethylationDiseaseEpigenetic ProcessFunctional disorderGene ExpressionGene Expression ProfileGene TargetingGenesInflammationInflammatoryInflammatory ResponseKnock-outLeukocytesMediatingMethylationMolecular TargetMorbidity - disease rateNF-kappa BNeutrophil ActivationNeutrophil InfiltrationNuclearNuclear TranslocationOrganPAR-1 ReceptorPathway interactionsPatternPeptide HydrolasesPhosphotransferasesPre-EclampsiaPregnancyPregnant WomenPrevention approachProteinsSigns and SymptomsSymptomsTestingVascular DiseasesWomanexperimental studyfetalin vivoinhibitor/antagonistmolecular targeted therapiesmortalityneutrophilnovelnovel strategiespregnancy disorderpreventtranscription factortreatment strategy
项目摘要
Preeclampsia is a hypertensive disorder of pregnancy that is a leading cause of maternal and fetal morbidity
and mortality. The cause of preeclampsia is not known, but the pregnancy specific expression of protease-
activated receptor-1 (PAR-1) on neutrophils may hold important keys to understanding the origins of the
disease and the underlying causes of maternal organ dysfunction. We propose a novel pathway through which
elevated levels of circulating proteases in preeclamptic women activate neutrophil PAR-1, which in turn
activates RhoA kinase (ROCK), which triggers translocation of TET2 (tet methylcytosine dioxygenase) and
inflammatory transcription factors, such as NF-B, into the nucleus resulting in specific changes in DNA
methylation that cause alterations in expression of genes involved in inflammation. This would be a pregnancy
specific inflammatory mechanism because PAR-1 is only expressed on neutrophils during pregnancy. Given
the extensive vascular infiltration of neutrophils in preeclampsia, this could explain vascular dysfunction leading
to clinical manifestation of symptoms. In Aim 1 we will determine if proteases activate pregnancy neutrophils by
a PAR-1, ROCK pathway to epigenetically regulate inflammatory genes via enzymatic de-methylation of DNA
by TET2, the TET protein expressed in leukocytes. We will determine if TET2 nuclear translocation coincides
with NF-B, and if the inflammatory response induced by proteases or present in neutrophils of preeclamptic
women can be prevented by inhibition of PAR-1 or ROCK. By using a TET2 knockout cell line, we will
determine if the expression of inflammatory genes requires TET2 activation. In Aim 2 we will determine
epigenetic alterations present in neutrophils of preeclamptic women that are due to TET2. We will identify
inflammatory gene loci de-methylated by TET, and then determine if de-methylation of these loci opens up
inflammatory transcription factor binding sites as a mechanism for increased gene expression. In Aim 3 we will
evaluate if proteases activate TET2 in neutrophils of normal pregnant women resulting in a pattern for
inflammatory genes mimicking preeclampsia. These experiments will provide evidence that elevated levels of
circulating proteases in preeclampsia could mediate the in vivo activation of neutrophils. These studies will
provide new information on pregnancy specific activation of neutrophils to mediate inflammatory response, and
may provide new strategies by identifying a molecular target for the treatment of preeclampsia with PAR-1
inhibitors.
先兆子痫是一种妊娠期高血压疾病,是导致孕产妇和胎儿发病的主要原因
and mortality.先兆子痫的原因尚不清楚,但妊娠特异性蛋白酶表达-
中性粒细胞上的活化受体-1(PAR-1)可能是理解这些疾病起源的重要关键。
疾病和母体器官功能障碍的根本原因。我们提出了一种新的途径,
先兆子痫妇女中循环蛋白酶水平升高激活中性粒细胞PAR-1,
激活RhoA激酶(ROCK),其触发TET 2(泰特甲基胞嘧啶双加氧酶)的易位,
炎症转录因子,如NF-κ B B,进入细胞核,导致DNA的特异性变化
甲基化导致炎症相关基因表达的改变。这就是怀孕
由于PAR-1在妊娠期间仅在中性粒细胞上表达,因此PAR-1是特异性炎症机制。给定
在先兆子痫中广泛的中性粒细胞血管浸润,这可以解释血管功能障碍导致
临床症状表现。在目标1中,我们将通过以下方法确定蛋白酶是否激活妊娠中性粒细胞:
PAR-1、ROCK通路通过DNA的酶促去甲基化表观遗传调节炎症基因
TET 2是白细胞中表达的泰特蛋白。我们将确定TET 2核易位是否一致
与NF-κ B B,如果炎症反应诱导的蛋白酶或目前在中性粒细胞的先兆子痫
女性可以通过抑制PAR-1或ROCK来预防。通过使用TET 2敲除细胞系,我们将
确定炎症基因的表达是否需要TET 2激活。在目标2中,我们将确定
由于TET 2,先兆子痫妇女的中性粒细胞中存在表观遗传改变。我们将确定
炎症基因位点被泰特去甲基化,然后确定这些位点的去甲基化是否开放
炎症转录因子结合位点作为增加基因表达的机制。在目标3中,
评估蛋白酶是否激活正常孕妇中性粒细胞中的TET 2,导致以下模式:
类似先兆子痫的炎症基因这些实验将提供证据表明,
先兆子痫中的循环蛋白酶可介导嗜中性粒细胞的体内活化。这些研究将
提供了关于妊娠特异性激活中性粒细胞介导炎症反应的新信息,
通过鉴定PAR-1治疗先兆子痫的分子靶点,
抑制剂的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT W WALSH其他文献
SCOTT W WALSH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT W WALSH', 18)}}的其他基金
Pregnancy Specific Protease Activation of PAR-1 and TET2 in Preeclampsia-Implications for Therapy
先兆子痫中 PAR-1 和 TET2 的妊娠特异性蛋白酶激活——对治疗的影响
- 批准号:
10190981 - 财政年份:2017
- 资助金额:
$ 32.16万 - 项目类别:
相似海外基金
Implication search for peripheral blood circulation cancer cellsas a Liquid biopsy target
外周血循环癌细胞作为液体活检目标的意义研究
- 批准号:
21H03021 - 财政年份:2021
- 资助金额:
$ 32.16万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Feasibility study to reach 'market readiness' with Recocoa's unique cacao based health bar, which is the only health nutrition bar which meets the European Health Claim (EFSA) in improving blood circulation by maintaining the elasticity of blood vessels.
Recocoa 独特的可可健康棒进行了“市场准备”的可行性研究,该健康棒是唯一符合欧洲健康声明 (EFSA) 通过保持血管弹性改善血液循环的健康营养棒。
- 批准号:
106360 - 财政年份:2020
- 资助金额:
$ 32.16万 - 项目类别:
Collaborative R&D
Feasibility study to reach 'market readiness' with Recocoa's unique cacao based health bar, which is the only health nutrition bar which meets the European Health Claim (EFSA) in improving blood circulation by maintaining the elasticity of blood vessels.
Recocoa 独特的可可健康棒进行了“市场准备”的可行性研究,该健康棒是唯一符合欧洲健康声明 (EFSA) 通过保持血管弹性改善血液循环的健康营养棒。
- 批准号:
72375 - 财政年份:2020
- 资助金额:
$ 32.16万 - 项目类别:
Feasibility Studies
Quantitative evaluation of blood circulation by deep learning in short time DCE-MRI
短时间深度学习DCE-MRI对血液循环的定量评估
- 批准号:
20K08041 - 财政年份:2020
- 资助金额:
$ 32.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of the micro blood circulation of the oral free flaps by indocyanin green near-infrared fluorescence angiography
吲哚青绿近红外荧光血管造影评价口腔游离皮瓣的微血循环
- 批准号:
19K10299 - 财政年份:2019
- 资助金额:
$ 32.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of a new treatment for pancreatic cancer by controlling immune response avoidance of blood circulation cancer stem cells
通过控制血液循环癌症干细胞的免疫反应避免建立胰腺癌新疗法
- 批准号:
19K09139 - 财政年份:2019
- 资助金额:
$ 32.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of ICG fluorescence contrast imaging analysis system specialized for evaluation of peripheral tissue blood circulation
开发专门评估末梢组织血液循环的ICG荧光对比成像分析系统
- 批准号:
19K18925 - 财政年份:2019
- 资助金额:
$ 32.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
用于从血液循环中靶向去除乳腺癌外泌体的血液净化器装置
- 批准号:
9620493 - 财政年份:2018
- 资助金额:
$ 32.16万 - 项目类别:
Development of the small blood circulation simulator to deepen the non-clinical evaluation of medical devices
开发小型血液循环模拟器深化医疗器械非临床评价
- 批准号:
18H03555 - 财政年份:2018
- 资助金额:
$ 32.16万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Experimental analysis of conservative therapy for blood circulation disorders using multifaceted optical measurement of nerve activity and peripheral blood flow
多层面光学测量神经活动和外周血流量保守治疗血液循环障碍的实验分析
- 批准号:
17K10764 - 财政年份:2017
- 资助金额:
$ 32.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)